Long-Term Follow-Up of ZUMA-1 Shows Significant Clinical Benefit (Video)
Dr. Brian Hill discusses the one-year follow-up data of the ZUMA-1 trial to confirm anti-CD19 CAR T cell therapy’s stability of response.
Long-Term Follow-Up of ZUMA-1 Shows Significant Clinical Benefit (Video)
Anti-CD19 CAR T cell therapy an option for patients with no others
Long-term follow-up results of ZUMA-1, a trial examining anti-CD19 CAR T cell therapy in non-Hodgkin lymphoma, show significant clinical benefit in patients with no curative treatment options, according to a study presented at ASH 2017 and published December 2017 in New England Journal of Medicine. Brian T. Hill, MD, PhD, staff in Cleveland Clinic Cancer Center’s Department of Hematology and Medical Oncology, is a coauthor.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Watch Dr. Hill discuss the study design and results below: